Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
dc.contributor.author | Riudavets, Mariona | |
dc.contributor.author | Mosquera Martínez, Joaquín | |
dc.contributor.author | García Campelo, María del Rosario | |
dc.contributor.author | Serra, Jorgina | |
dc.contributor.author | Anguera, Georgia | |
dc.contributor.author | Gallardo, Pablo | |
dc.contributor.author | Sullivan, Ivana | |
dc.contributor.author | Barba, Andrés | |
dc.contributor.author | Del Carpio, Luís | |
dc.contributor.author | Barnadas, Agustí | |
dc.contributor.author | Gich, Ignasi | |
dc.contributor.author | Majem, Margarita | |
dc.date.accessioned | 2022-03-16T08:37:20Z | |
dc.date.available | 2022-03-16T08:37:20Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2234-943X | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/33014837 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16254 | |
dc.description.abstract | Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. We evaluated outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents in relation to the presence of irAEs and the reasons for using corticosteroids: whether for palliative cancer-related reasons or for the management of irAEs. Methods: Clinical outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents were calculated with regard to the presence of irAEs and the use of corticosteroids. A landmark analysis was performed to avoid immortal time bias due to the time-dependent nature of irAEs. Results: Out of a total of 267 patients, the 56.9% of patients who experienced irAEs had significantly improved outcomes. In the landmark analysis, median progression-free survival (PFS) was 12.4 months for patients with irAEs vs. 4.1 months for patients without irAEs (p < 0.001), while median overall survival (OS) was 28.2 vs. 12.5 months, respectively (p < 0.001). Likewise, objective response and disease control rates were significantly higher in patients experiencing irAEs: 48.6 vs. 22.8% and 77.1 vs. 39.6% (p < 0.001), respectively. Median OS was significantly shorter for patients receiving >/=10 mg of prednisone equivalent daily for cancer-related symptoms than for the rest of patients (<10 mg prednisone equivalent daily or for management of irAEs): 6 vs. 15.9 months (p < 0.001). Conclusions: IrAEs were associated with improved efficacy in advanced NSCLC patients when a landmark analysis was applied. Patients receiving corticosteroids had significantly poorer outcomes when they were used for cancer-related symptoms. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents | en |
dc.type | Journal Article | es |
dc.authorsophos | Riudavets, Mariona;Mosquera, Joaquin;Garcia-Campelo, Rosario;Serra, Jorgina;Anguera, Georgia;Gallardo, Pablo;Sullivan, Ivana;Barba, Andrés;Del Carpio, Luís;Barnadas, Agustí;Gich, Ignasi;Majem, Margarita | |
dc.identifier.doi | 10.3389/fonc.2020.01677 | |
dc.identifier.pmid | 33014837 | |
dc.identifier.sophos | 36091 | |
dc.journal.title | FRONTIERS IN ONCOLOGY | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médica | es |
dc.relation.publisherversion | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505083/pdf/fonc-10-01677.pdf | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | CHUAC | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 10. | es |